HEPA Archives - Page 4 of 11

Developments

Hepion Pharma food effect study with rencofilstat published

The peer-reviewed journal, Clinical Pharmacology in Drug Development, published the results of a clinical trial examining the effect of food on the oral bioavailability of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug...

October 21, 2022

Markets

Cantor sees Hepion Pharma potentially emerging from under the radar

In a new research report, Cantor Fitzgerald writes that Hepion Pharmaceuticals (NASDAQ:HEPA) is a company that has largely flown under the radar despite already achieving some early proof-of-concept evidence and having...

September 21, 2022

Developments

Hepion collaborators to present new rencofilstat findings in alcohol-related liver disease

Hepion Pharmaceuticals’ (NASDAQ:HEPA) collaborators from London’s Institute of Hepatology will present new findings on Hepion’s cyclophilin inhibitor, rencofilstat, in an awarded oral presentation at the...

September 14, 2022

Developments

Hepion initiates dosing in Phase 2 ALTITUDE-NASH liver function trial

Hepion Pharmaceuticals (NASDAQ:HEPA) dosed the first stage 3 (F3) NASH subject with rencofilstat in a Phase 2 clinical trial designed to measure hepatic function. The trial is being conducted in collaboration with...

September 12, 2022

Developments

Hepion Pharmaceuticals initiates Phase 2b ASCEND-NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) screened the first subject in its ASCEND-NASH clinical trial being conducted at up to 121 sites in seven countries, including 85 sites in the U.S. The Phase 2b, randomized, multi...

August 31, 2022

Executive Moves

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...

June 28, 2022

Developments

Hepion receives FDA orphan drug designation for rencofilstat in HCC

The FDA granted orphan drug designation to Hepion Pharmaceuticals’ (NASDAQ:HEPA) drug candidate, rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of hepatocellular...

June 20, 2022

Developments

Hepion to present 5 posters at EASL International Liver Congress 2022

Hepion Pharmaceuticals (NASDAQ:HEPA) said five abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress taking place June 22...

June 15, 2022

Executive Moves

Hepion names accomplished life sciences veteran Launa Aspeslet as COO

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Launa Aspeslet, Ph.D., RAC, as chief operating officer to support the company’s rencofilstat clinical program. A versatile C-level executive with more than 25 years of...

June 14, 2022

Developments

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Todd Hobbs, M.D. and CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), gave a clinical presentation entitled, “Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” at the Global NASH Congress...

May 27, 2022

Tag - HEPA

Hepion Pharma food effect study with rencofilstat published

Cantor sees Hepion Pharma potentially emerging from under the radar

Hepion collaborators to present new rencofilstat findings in alcohol-related liver disease

Hepion initiates dosing in Phase 2 ALTITUDE-NASH liver function trial

Hepion Pharmaceuticals initiates Phase 2b ASCEND-NASH trial

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Hepion receives FDA orphan drug designation for rencofilstat in HCC

Hepion to present 5 posters at EASL International Liver Congress 2022

Hepion names accomplished life sciences veteran Launa Aspeslet as COO

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

General

More